1 / 40

Use of AMS in low radioactive dose human AME studies

Use of AMS in low radioactive dose human AME studies. GMP Journées des 04 et 05 Février 2004 Distribution et Transporteurs dans les études de pharmacocinétique Paris Geert Mannens, Ph.D. Preclinical Pharmacokinetics Johnson&Johnson Pharmaceutical Research&Development ,

amaya-bridges
Download Presentation

Use of AMS in low radioactive dose human AME studies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Use of AMS in low radioactive dose human AME studies GMP Journées des 04 et 05 Février 2004 Distribution et Transporteurs dans les études de pharmacocinétique Paris Geert Mannens, Ph.D. Preclinical PharmacokineticsJohnson&Johnson Pharmaceutical Research&Development, A division of Janssen Pharmaceutica N.V. Turnhoutseweg 30B-2340 BeerseBelgium

  2. Outline • AMS Technology • Evaluation of AMSPreclinical and clinical experiences • Conclusions • Advantages • Disadvantages • Perspectives

  3. Outline • AMS Technology • Evaluation of AMSPreclinical and clinical experiences • Conclusions • Advantages • Disadvantages • Perspectives

  4. AMS Accelerator Mass Spectrometry • Nuclear physics technique • Developed in the USA in the mid 70’s • Primarily used for archaeological (carbon) dating • Mass spectrometer coupled to tandem accelerator • Following graphitization, isotopes are measured on the basis of their m/z ratio • Highly sensitive determination of 14CLOQ: 0.005-0.86 dpm/ml (serum extract-faeces)upper limit of detection is 50 dpmideally 10 dpm injected

  5. Sample preparation Graphitisation process Carbon in biological sample (+ 14C-depleted carbon carrier) CuO2 900°COxidation Cu CO2 H2 from 500°C withTiH2 + Zn Co Catalyst Reduction H2O Graphite (0.5-2 mg) (inorganic carbon)

  6. AMS Diagram of an accelerator mass spectrometer (30 m in length !) Isotopes are accelerated (Tandem Van de Graaff accelerator), electrons are stripped (argon gas) and positive ions are separated using conventional mass spectrometer based on their m/z ratio. 12,13,14C+1to+6 12,13C4+ 12,13,14C- 14C4+

  7. AMS Output • not an absolute value, but 14C/13C or 14C/12C ratio (remember carbon dating) • AMS data are expressed as the amount of 14C per mg carbon or aspMC (percent modern carbon). Calibration is done with standards with known pMC values. 100 pMC = 1 14C atom/1.18x101212C atoms or 97.6 attomole 14C per mg carbon 100 pMC = 13.56 dpm 14C/g C • dpm per g sample is calculated after determining the carbon content with a C,H,N analyser (at 1 g/ml) (dpm 14C/g C) x (% w/v C in sample) = dpm 14C/ml • 3-9 orders of magnitude more sensitive than LSC (atto- to zetogram for 14C 10-18 - 10-21 grams).

  8. 6 X 105 atoms 14C 1 attomole 14C (t½= 5730 years) ß- AMS scintillation counter 1000 counts in 14 years 1000 counts in 2 minutes Comparing AMS to scintillation counting AMS measures the number of atoms in the sample, while scintillation counters measure the infrequent radioactive decay events in the sample (in any year less than 0.012 % of 14C decays).

  9. Outline • AMS Technology • Evaluation of AMSPreclinical and clinical experiences • Conclusions • Advantages • Disadvantages • Perspectives

  10. Evaluation of AMS [1]Dilution experiment Analysis of plasma samples, urine samples and methanolic extracts of faeces samples, collected in a clinical study with a convential radioactive dose of a 14C-labelled compound, by LSC (without sample dilution) or by AMS after 600- (< 1.0 µSv) or 5000-fold (< 1 nCi) dilution of the samples.

  11. Evaluation of AMS [1] Dilution experiment

  12. Evaluation of AMS [1] Dilution experiment

  13. Evaluation of AMS [1] Dilution experiment: conclusion • Fairly good to good comparison after both 600- and 5000-fold dilution.

  14. Evaluation study [2] • Determination of the mass balance and plasma kinetics after single oral administration of a 14C-labelled compound to male and female Wistar rats at a convential radioactive dose (sample analysis by LSC) or at a very low radioactive dose (sample analysis by AMS).

  15. Evaluation study [2] R115777 (oncology compound) was selected as test item on the basis of the following considerations: • High radioactive dose preclinical study already performed  optimal design for low radioactive dose study. • Relatively simple metabolism (only 3-5 metabolites). • The mass balance study in healthy volunteers was scheduled to be performed with AMS.

  16. Evaluation study [2] : Dosing

  17. Evaluation study [2] : sample analysis • Plasma samples, urine samples and methanolic extracts of faeces samples were analysed by LSC (high radioactive dose study) or AMS (low radioactive dose study). • Faecal residues were analysed by LSC of the oxidised samples (high radioactive dose study) or AMS (low radioactive dose study).

  18. Evaluation study [2] : results Faeces (methanolic extracts) 100 90 LSC AMS 80 70 60 % of dose 50 40 30 20 10 0 0-24 h 24-48 h 48-72 h 72-96 h 0-24 h 24-48 h 48-72 h 72-96 h Male rats Female rats

  19. Evaluation study [2] : results

  20. Evaluation study [2] : results

  21. Evaluation study [2] : results Correlation between the high and low radioactive dose was: • Reasonable to good for faecal excretion. • Poor for urinary excretion (presumably due to contamination of the urine/faeces collection systems). • Poor for plasma concentrations determined without protein precipitation (presumably due to high background radioactivity). • Reasonable for plasma concentrations determined with protein precipitation.

  22. Conclusions for mass balance and plasma kinetics studies in healthy volunteers The problems encountered in the rat study are not expected to occur in human AME studies, because: • It is possible to collect urine and faeces with only minimal risk of contamination with 14C. • It is possible to collect blank blood/plasma and blank urine from each individual subject, thus allowing for subtraction of the appropriate background.

  23. Conclusions for mass balance and plasma kinetics studies in healthy volunteers Lessons learned: • Laboratories, materials or instruments that have been previously used in high radioactive dose studies can not be used for low radioactive dose studies involving AMS analysis, not even after extensive cleaning. • Total radioactivity in plasma should be determined with and without protein precipitation. A gentle protein precipitation method should be used to maximise the recovery.

  24. Human AMS study: study preparations • Purchase of new glassware, faeces containers, Büchner filters, etc. • Allocation of laboratory areas that had not been used for activities involving 14C-labelled materials. • Repeated cleaning of all devices, areas and instruments that were used for activities with 14C-labelled materials. • AMS analysis of swabs taken from all relevant and potentially contaminated devices, areas and instruments, clinical unit. • Clinical unit: non-radioactive area

  25. Human AMS study: Dosing Mass balance and plasma kinetics study in healthy male adult subjects after single oral administration of 14C-R115777Garner R.C. et al. DMD 30:823-830, 2002. • Number of subjects : 4 • Route: Oral solution • Total dose: 50 mg • Radioactive dose: 1.27 kBq = 34.4 nCi = ~76,000 DPM • Radiation exposure: 0.9 µSv For comparison: • Thorax X-ray: 100-200 µSv • Cosmic radiation: 3 µSv/day

  26. Human AMS study : Sample collection • Urine was collected once before dosing (blank) and in intervals from 0-4, 4-8, 8-24 , 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 h after dosing. • Faeces was collected once before dosing (blank) and per stool up to 168 h after dosing. • Blood (plasma) was collected once before dosing (blank) and at 1, 2, 3, 4, 6, 8, 24, 32, 48, 72, 96 and 168 h after dosing.

  27. Human AMS study : Sample analysis • Blood samples were collected and plasma was separated. • Faeces samples were homogenised in and extracted with methanol. The methanolic faeces exctracts and the faecal residues were separated by filtration. The faecal residues were dried and ground. • Radioactivity concentrations in urine samples, methanolic faeces extracts and faecal residues were determined by AMS. • Radioactivity concentrations in plasma samples were determined by AMS with and without protein precipitation. • A pool of urine samples, a pool of methanolic faeces extracts and a pool of plasma samples were injected onto a HPLC column. Eluent fractions were collected. Radioactivity concentrations in individual eluent fractions were determined by AMS.

  28. Human AMS study : Sample analysis Xceleron (previous CBAMS, Centre for Biomedical Accelerator Mass Spectrometry, York, UK) • Total radioactivity in dosing solution (LSC) (CBAMS)(Packard Tri-Carb TR/SL 2770)4338.59 dpm/ml • Total radioactivity (CBAMS, NEC 15SDH-2 Pelletron) inurine : 45 individual samplesfaeces : 41 individual samples (extract + residue) plasma : 54 individual samples

  29. Human AMS study : Sample analysis • metabolite profiling : AMS after HPLC fractionation, no hyphenated technique (CBAMS) : 2 runs per sample • 1 urine sample: before and after enzymatic hydrolysis • 1 extract of faeces • 1 plasma sample : 3-h overall pool before and after enzymatic hydrolysis • bioanalysis (Janssen) • metabolite identification (Janssen): • comparison of HPLC retention time with known standards • confirmation by LC-MSMS

  30. Human AMS study Total excretion in urine and faeces Garner R.C. et al. DMD 30:823-830, 2002

  31. Human AMS study Total radioactivity and unchanged R115777 in plasma Garner R.C. et al. DMD 30:823-830, 2002

  32. 1.20 1.00 -glu Urine 0.80 +glu Urine dpm per fraction 0.60 0.40 0.20 0.00 0 10 20 30 40 50 60 Time (min) Human AMS study Metabolite profile in urine R115777 R115777- glucuronide R130525 Garner R.C. et al. DMD 30:823-830, 2002

  33. Human AMS study Metabolite profile in faeces Garner R.C. et al. DMD 30:823-830, 2002

  34. Human AMS study Metabolite profile in plasma Garner R.C. et al. DMD 30:823-830, 2002

  35. Human AMS study Conclusions • AMS is a suitable method for the determination of the mass balance after giving a very low radioactive dose. • Radioactivity concentrations in non-pretreated plasma samples may be inaccurate, due to high background levels of 14C (~0.5 dpm/ml). • Radioactivity concentrations in deproteinised plasma samples may be underestimated, due to occlusion of radioactivity in precipitated proteins. • AMS analysis of HPLC eluent fractions allows for an evaluation of metabolite profiles, provided the number of metabolites is limited ( 5).

  36. Outline • AMS Technology • Evaluation of AMSPreclinical and clinical experiences • Conclusions • Advantages • Disadvantages • Perspectives

  37. AMS ADVANTAGES OF AMS • Radioactive dose in humans may be 500-5000 times lower (1 µSv, now ~ 500-1000 µSv) • Less preclinical data needed for ethics committee • Opens possibility to conduct studies that were previously impossible

  38. AMS DISADVANTAGES OF AMS • On-line metabolite profiling is not possible • Synthesis of high specific activity 14C labelled compound is still necessary • Contamination !! • Also senstive for endogenous 14C (importance of predose samples)

  39. AMS Interference from endogenous 14C0.024 dpm of a plasma extract injected

  40. Future perspectives approach to the application of AMS in clinical studies Ethical considerations • slow elimination : tissue retention / long half-life • depot formulation Scientific considerations • Very potent compounds – extreme low dose • inhalation/dermal application : bioavailability studies with a high radioactive dose • evidence for relatively uncomplicated metabolism • Limitation with the specific radioactivity (autoradiolysis) • micro-dosing concept under evaluation

More Related